NSAIDS or paracetamol, alone or combined with opioids, for cancer pain

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 7, 2015, Pages

  Mcnicol, Ewan D ^a   Strassels, Scott ^b   Goudas, Leonidas ^a   Lau, Joseph ^c   Carr, Daniel B ^d  

^a TUFTS MEDICAL CENTER   (United States)

^b Healthcare Policies and Economic Outcomes   (United States)

^c BROWN UNIVERSITY   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRIORITY JOURNAL; RETRACTED ARTICLE; REVIEW; COMPLICATION; FEMALE; HUMAN; MALE; NEOPLASM; PAIN; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANALGESIC AGENT; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FEMALE; HUMANS; MALE; NEOPLASMS; PAIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84945948623     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD005180.pub2     Document Type: Review

References (74)

1. Bjorkman R, Ullman A, Hedner J. Morphine-sparing effect of diclofenac in cancer pain. European Journal of Clinical Pharmacology 1993;44(1):1-5.
2. Bosek V, Miguel R. Comparison of morphine and ketorolac for intravenous patient-controlled analgesia in postoperative cancer patients. Clinical Journal of Pain 1994;10(4):314-8.
3. Carlson RW, Borrison RA, Sher HB, Eisenberg PD, Mowry PA, Wolin EM. A multiinstitutional evaluation of the analgesic efficacy and safety of ketorolac tromethamine, acetaminophen plus codeine, and placebo in cancer pain. Pharmacotherapy 1990;10(3):211-6.
4. Chary S, Goughnour BR, Moulin DE, Thorpe WR, Harsanyi Z, Darke AC. The dose-response relationship of controlled-release codeine (Codeine Contin) in chronic cancer pain. Journal of Pain & Symptom Management 1994;9(6):363-71.
5. Corli O, Cozzolino A, Scaricabarozzi I. Nimesulide and diclofenac in the control of cancer-related pain. Comparison between oral and rectal administration. Drugs 1993;46(suppl 1):152-5.
6. Danninger R, Jaske R, Beubler E. Randomized crossover-comparison of 2g- and 4g- doses of Paracetamol per day in the case of mild to moderate pain caused by head and neck cancers [Randomisierter Crossover-Vergleich von 2g- und 4g- Tagesdosen Paracetamol bei leicht- bis mittelgradigen Schmerzen von Tumoren im Kopf-Hals-Bereich]. European Journal of Pain 1993;14(1):14-18.
7. Dellemijn PL, Verbiest HB, van Vliet JJ, Roos PJ, Vecht CJ. Medical therapy of malignant nerve pain. A randomised double-blind explanatory trial with naproxen versus slow-release morphine. European Journal of Cancer 1994;30A(9):1244-50.
8. Estape J, Vinolas N, Gonzalez B, Ingles F, Bofill T, Guzman MC, Tarrago E. Ketorolac, a new non-opioid analgesic: a double-blind trial versus pentazocine in cancer pain. Journal of International Medical Research 1990;18(4):298-304.
9. Ferrer-Brechner T, Ganz P. Combination therapy with ibuprofen and methadone for chronic cancer pain. American Journal of Medicine 1984;77(1A):78-83.
10. Frankendal B. Clinical testing of a new analgesic combination on cancer patients in chronic pain [Klinisk provning av ny analgetikakombination pa cancerpatienter med kroniska smartor]. Lakartidningen 1973;70(10):949-51.
11. Gallucci M, Toscani F, Mapelli A, Cantarelli A, Veca G, Scaricabarozzi I. Nimesulide in the treatment of advanced cancer pain. Double-blind comparison with naproxen. Arzneimittel-Forschung 1992;42(8):1028-30.
12. Johnson JR, Miller AJ. The efficacy of choline magnesium trisalicylate (CMT) in the management of metastatic bone pain: a pilot study. Palliative Medicine 1994;8(2):129-35.
13. Levick S, Jacobs C, Loukas DF, Gordon DH, Meyskens FL, Uhm K. Naproxen sodium in treatment of bone pain due to metastatic cancer. Pain 1988;35(3):253-8.
14. Lomen PL, Samal BA, Lamborn KR, Sattler LP, Crampton SL. Flurbiprofen for the treatment of bone pain in patients with metastatic breast cancer. American Journal of Medicine 1986;80(3A):83-7.
15. Martino G, Ventafridda V, Parini J, Emanueli A. A controlled study on the analgesic activity of indoprofen in patients with cancer pain. In: Bonica JJ, Albe-Fessard D editor(s). Pharmacological Agents in Chronic Pain, Advances in Pain Research and Therapy. Vol. 1, New York: Raven Press, 1976:573-8.
16. Minotti V, Patoia L, Roila F, Basurto C, Tonato M, Pasqualucci V, et al. Double-blind evaluation of analgesic efficacy of orally administered diclofenac, nefopam, and acetylsalicylic acid (ASA) plus codeine in chronic cancer pain. Pain 1989;36(2):177-83.
17. Minotti V, Betti M, Ciccarese G, Fumi G, Tonato M, Del Favero A. A double-blind study comparing two single-dose regimens of ketorolac with diclofenac in pain due to cancer. Pharmacotherapy 1998;18(3):504-8.
18. Minotti V, De Angelis V, Righetti E, Celani MG, Rossetti R, Lupatelli M, Tonato M, Pisati R, Monza G, Fumi G, Del Favero A. Double-blind evaluation of short-term analgesic efficacy of orally administered diclofenac, diclofenac plus codeine, and diclofenac plus imipramine in chronic cancer pain. Pain 1998;74(2-3):133-7.
19. Moertel CG, Ahmann DL, Taylor WF, Schwartau N. Aspirin and pancreatic cancer pain. Gastroenterology 1971;60(4):552-3.
20. Moertel CG, Ahmann DL, Taylor WF, Schwartau N. Relief of pain by oral medications. A controlled evaluation of analgesic combinations. JAMA 1974;229(1):55-9.
21. Pannuti F, Robustelli della Cuna G, Ventaffrida V, Strocchi E, Camaggi CM. A double-blind evaluation of the analgesic efficacy and toxicity of oral ketorolac and diclofenac in cancer pain. The TD/10 recordati Protocol Study Group. Tumori 1999;85(2):96-100.
22. Rodriguez M, Barutell C, Rull M, Galvez R, Pallares J, Vidal F, Aliaga, Moreno J, Puerta J, Ortiz P. Efficacy and tolerance of oral dipyrone versus oral morphine for cancer pain. European Journal of Cancer 1994;30A(5):584-7.
23. Sacchetti G, Camera P, Rossi AP, Martioni A, Bruni G, Pannuti F. Injectable ketoprofen vs. acetylsalicylic acid for the relief of severe cancer pain: a double-blind, crossover trial. Drug Intelligence & Clinical Pharmacy 1984;18:403-6.
24. Saxena A, Andley M, Gnanasekaran N. Comparison of piroxicam and acetylsalicylic acid for pain in head and neck cancers: a double-blind study. Palliative Medicine 1994;8(3):223-9.
25. Stambaugh JE. Analgesic equivalence of Tylox and Percodan: double-blind crossover study of patients with pain from malignancy. Current Therapeutic Research 1980;27(2):302-9.
26. Stambaugh JE Jr. Additive analgesia of oral butorphanol/acetaminophen in patients with pain due to metastatic carcinoma. Current Therapeutic Research 1982;31(3):386-92.
27. Stambaugh J, Drew J. A double-blind parallel evaluation of the efficacy and safety of a single dose of ketoprofen in cancer pain. Journal of Clinical Pharmacology 1988;28(12 Suppl):S34-39.
28. Stambaugh JE Jr, Drew J. The combination of ibuprofen and oxycodone/acetaminophen in the management of chronic cancer pain. Clinical Pharmacology & Therapeutics 1988;44(6):665-9.
29. Staquet MJ. A double-blind study with placebo control of intramuscular ketorolac tromethamine in the treatment of cancer pain. J Clin Pharmacol 1989;29(11):1031-6.
30. Staquet M, Renaud A. Double-blind, randomized trial of piroxicam and codeine in cancer pain. Current Therapeutic Research 1993;53(4):435-9.
31. Strobel VE. Drug therapy in severe tumor pain. Comparative study of a new combination preparation versus diclofenac-Na. [Medikamentose Therapie bei starken Tumorschmerzen. Vergleichsstudie eines neuen Kombinationspraparats versus Diclofenac-Na]. Fortschritte der Medizin 1992;110(22):411-4.
32. Sunshine A, Olson NZ. Analgesic efficacy of ketoprofen in postpartum, general surgery, and chronic cancer pain. J Clin Pharmacol 1988;28(Suppl):S47-S54.
33. Tonachella R, Curcio C, Grossi E. Diclofenac sodium in cancer pain: A double-blind within-patients comparison with pentazocine. Current Therapeutic Research 1985;37(6):1130-3.
34. Toscani F, Piva L, Corli O, Gallucci M, Speranza R, Tamburini M, et al. Ketorolac versus diclofenac sodium in cancer pain. Arzneimittel-Forschung 1994;44(4):550-4.
35. Turnbull R, Hills LJ. Naproxen versus aspirin as analgesics in advanced malignant disease. Journal of Palliative Care 1986;1(2):25-8.
36. Ventafridda V, Martino G, Mandelli V, Emanueli A. Indoprofen, a new analgesic and anti-inflammatory drug in cancer pain. Clinical Pharmacology & Therapeutics 1975;17(3):284-9.
37. Ventafridda V, Toscani F, Tamburini M, Corli O, Gallucci M, Gottlieb A, Speranza R, De Conno F. Sodium naproxen versus sodium diclofenac in cancer pain control. Arzneimittel-Forschung 1990;40(10):1132-4.
38. Ventafridda V, De Conno F, Panerai AE, Maresca V, Monza GC, Ripamonti C. Non-steroidal anti-inflammatory drugs as the first step in cancer pain therapy: double-blind, within-patient study comparing nine drugs. Journal of International Medical Research 1990;18(1):21-9.
39. Weingart WA, Sorkness CA, Earhart RH. Analgesia with oral narcotics and added ibuprofen in cancer patients. Clinical Pharmacy 1985;4(1):53-8.
40. Wool C, Prandoni P, Polistena P, Ruol A. Ketorolac suppositories in the treatment of neoplastic pain: A randomized clinical trial versus diclofenac. Current Therapeutic Research 1991;49(5):854-61.
41. Yalcin S, Gullu I, Tekuzman G, Savas C. Ketorolac tromethamine in cancer pain. Acta Oncologica 1997;36(2):231-2.
42. Yalcin S, Gullu IH, Tekuzman G, Savas C, Firat D. A comparison of two nonsteroidal antiinflammatory drugs (diflunisal versus dipyrone) in the treatment of moderate to severe cancer pain: a randomized crossover study. American Journal of Clinical Oncology 1998;21(2):185-8.
43. Cantarelli A, Giannunzio D, Ligorio L, Mapelli A, Veca G, Gallucci M, Toscani F. Comparison of nimesulide and naproxen sodium in the control of cancer pain. Minerva Anestesiologica 1991;57(10):1103-4.
44. Epstein JB, Stevenson-Moore P. Benzydamine hydrochloride in prevention and management of pain in oral mucositis associated with radiation therapy. Oral Surgery, Oral Medicine, Oral Pathology 1968;62:145-8.
45. Fuccella LM, Conti F, Corvi G, Mandelli V, Randelli M, Stefanelli G. Double-blind study of the analgesic effect of indoprofen (K 4277). Clinical Pharmacology & Therapeutics 1975;17(3):277-83.
46. Martino G, Emanueli A, Mandelli V, Ventafridda V. A controlled study of the analgesic effect of two non-steroidal anti-inflammatory drugs in cancer pain. Arzneimittel-Forschung 1978;28(9):1657-9.
47. Pellegrini A, Massidda B, Pellegrini P, Defraia E, Usai A, Parrinello L, Bruni G, Rigamonti G, Sacchetti G. Effect of i.v. indoprofen on cancer pain and serum prolactin and growth hormone levels - a controlled pharmacologic study vs i.m. morphine and placebo. International Journal of Clinical Pharmacology, Therapy and Toxicology 1983;21(9):483-486.
48. Puglisi G, Garagiola U. Pirprofen and Pentazocine in the treatment of cancer pain. Current Therapeutic Research 1989;45(3):333-338.
49. Stambaugh JE Jr, Tejada F, Trudnowski RJ. Double-blind comparisons of zomepirac and oxycodone with APC in cancer pain. Journal of Clinical Pharmacology 1980;20(4 Pt 2):261-70.
50. Stambaugh JE Jr, Sarajian C. Analgesic efficacy of zomepirac sodium in patients with pain due to cancer. Journal of Clinical Pharmacology 1981;29(11):1031-6.
51. Stambaugh JE Jr. Analgesic efficacy, safety and acceptability of zomepirac sodium in comparison to morphine sulfate in the treatment of pain secondary to malignancy. Current Therapeutic Research 1982;31(6):922-9.
52. Toscani F, Barosi K, et al. Sodium Naproxen: continuous subcutaneous infusion in neoplastic pain control. Palliative Medicine 1989;3:207-11.
53. Toscani F, Gallucci M, Scaricabarozzi I. Nimesulide in the treatment of advanced cancer pain. Double-blind comparison with naproxen. Drugs 1993;46(Suppl 1):156-8.
54. American Cancer Society. Textbook of Clinical Oncology. Second Edition. Washington, D.C.: Pan American Health Organization, 1995.
55. British Medical Association/Royal Pharmaceutical Society. British National Formulary. Vol. Number 43, Wallingford, United Kingdom: Pharmaceutical Press, 2002.
56. Cepeda MS, Africano JM, Polo R, Alcala R, Carr DB. What decline in pain intensity is meaningful to patients with acute pain?. Proceedings of the 10th World Congress on Pain, Progress in Pain Research and Management. Seattle: IASP Press, 2003; Vol. 24:601-9.
57. Davar G. What causes cancer pain?. Pain Clinical Updates 2002;10(2):1-4.
58. Eisenberg E, Berkey CS, Carr DB, et al. Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: a meta-analysis. Journal of Clinical Oncology 1994;12:2756-65.
59. Anon. Drug Facts and Comparisons. St Louis, MS: Wolters Kluwer, 2002.
60. Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL. Defining the clinically important difference in pain outcome measures. Pain 2000;88:287-94.
61. Farrar JT, Young JP, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58.
62. Foley KM, Gelband H. Improving palliative care for cancer. Institute of Medicine, Washington, D.C. National Academy Press, 2001.
63. Goudas L, Carr DB, Bloch R, et al. Management of Cancer Pain. Vol. 1&2, Rockville, MD: Agency for Healthcare Research and Quality, 2001.
64. Jacox A, Carr DB, Payne R, et al. Management of Cancer Pain. Clinical Practice Guideline. 9th Edition. Rockville, MD: Agency for Health Care Policy and Research, 1994.
65. Jadad A, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clin Trials 1996;17:1-12.
66. Levin D, Cleeland CS. Public attitudes towards cancer pain. Cancer 1985;56:2337-9.
67. McCaffery M, Pasero C. Opioid Analgesics. In: Bowlus B editor(s). Pain. 2nd Edition. St. Louis: Mosby, Inc, 1999:161-299.
68. McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, Lau J, Carr DB. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. Journal of Pain 2002;4(5):231-256.
69. McQuay HJ, Moore RA. Paracetamol with and without codeine in acute pain. Postoperative analgesia and vomiting, with special reference to day-case surgery: a systematic review. Winchester, England: Health Technology Assessment, 1998:2:ii-230.
70. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncology 2001;2:533-43.
71. Steinbach G, Lynch P, Phillips R, et al. The effects of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. New England Journal of Medicine 2000;342:1946-52.
72. Ventafridda V, Caraceni A, Gamba A. Field testing of the WHO guidelines for cancer pain relief: summary report of demonstration projects. In: Foley KM, Bonica JJ, Ventafridda V editor(s). Proceedings of the Second International Congress on Pain. Advances in Pain Research and Therapy. Vol. 16, New York: Raven Press, Ltd, 1990:451-64.
73. World Health Organisation. Cancer pain relief. 2nd Edition. Geneva: WHO, 1996.
74. Worthington HV, Clarkson JE, Eden OB. Interventions for treating oral mucositis for patients with cancer receiving treatment. Cochrane Database of Systematic Reviews 2004, Issue 2. Art. No.: CD001973.pub2. [DOI: 10.1002/14651858.CD001973.pub2]